+30.3%
SCHD vs GSK
+31.2%
-1.0%
-4.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.8% | -1.9% | +1.1% | -0.4% |
| 7D | -0.3% | -1.8% | +1.5% | 0.0% |
| 30D | +3.4% | -2.2% | +5.6% | +3.8% |
| 3M | +7.6% | -1.8% | +9.4% | +7.9% |
| 6M | +12.2% | -10.6% | +22.8% | +13.9% |
| YTD | +29.0% | +4.4% | +24.5% | +27.8% |
| 1Y | +30.3% | +30.4% | -0.1% | +25.5% |
| All | +30.3% | +31.2% | -1.0% | +25.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling